TRANSGENIC PLANTS HAVING RESISTANCE TO A FUNGAL DISEASE

Abstract: The present invention provides novel nucleic acid sequences, which upon their transformation into plants, provide the later with resistance to plant fungal diseases, in particular to downy mildew disease. The nucleic acids of the invention, one or more thereof, are transformed into a plant cell, from which said plant is generated. Such plants also form part of the invention. The nucleic acid of the invention may also be used for mass production of biologically functional proteins or peptides encoded thereby.

Description: TRANSGENIC PLANTS HAVING RESISTANCE TO A FUNGAL DISEASE FIELD OF THE INVENTION 5 The present invention is generally in the filed of biotechnology and in particular to novel, biologically functional nucleic acid sequences and their different uses. e.g. in agriculture. PRIOR ART The following is a list of prior art which is considered to be pertinent for ] o describing the state of the art in the field of the invention. Acknowledgement of these references herein will be made by indicating the number from their list below within brackets. 1. Cohen Y. Spencer MD, ed. The Downy Mildew, London: Academic Press. 341 -354 (1987); 15 2. Kenigsbuch D and Cohen Y. Plant Disease 73:994-996 (1989); 3. Kenigsbuch D and Cohen Y. Plant Disease 76:615-617 ( 1992); 4. Pitrat F.. Cucurbit Genetic Cooperative Reporter 9: 111-120 (1986); 5. Balass M. et al. Physiological and Molecular Plant Pathology 43: 11-20 ( 1993); 0 6. Thomas C.E.. HortScience 21:329 (1986). BACKGROUND OF THE INVENTION Downy mildew of cucurbits caused by the fungus Pseudoperonospora cubensis (Berk, et Curt.) Rost. is one of the most serious diseases of muskmelones (Cucumis melo L.) and cucumbers (Cucumis sativus L.) in temperate regions of the 5 world. This fungus consist of 5 phatotypes and it has been reported that muskmelon ( C. melo var. reticulatus) is susceptible to all five pathotypes of this fungus [Thomas C.E. et al. Phtopathology 77:1621-1624 (1987)]. Λ high el of resistance against pathotype 3 of P. cubensis in C melo var. reticulatus line PI 1241 1 1 was reported' 1 '. The PI 1241 1 1 was also found to be highh resistant to pathotype 1 and 2 in Japan and pathotype 4 and 5 in the USA [6] . o breeding lines were developed from PI 1241 1 1 : (1) PI 1241 1 IF in Israel [Cohen Y. and Eyal H.. Phytoparasitica 15: 187-195 ( 1987)] and (2) MR1 in the USA [6] . Both breeding lines produced fruits of low quality and carried two incompletely dominant genes against P cubensis. which were designated P i and Pc 2 ■ ln addition, resistance of PI 1241 1 1 to downy mildew was found to be temperature-dependent' 5] . At a low icmperature of colonization (about 12°C). resistance of both PI 1241 1 IF and F | ( ) in breeds, were found to be reduced, suggesting temperature regulation at the level of gene expression or function of the gene product. Λ unique protein of approximately 45kDa (P45) was shown to be constitutive!)' produced in the resistant PI 1241 1 1 F. This protein is a soluble, cytoplasmic protein found in the plants leaves and cotyledons. Analyzing Mendelian segregates of a cross between PI 124111 F and a susceptible cultivar revealed that the level of resistance was positively correlated with the amount of P45 in leaf extracts' . GLOSSARY In the following description and claims use will be made, at times, with a variety of terms, and the meaning of such terms as they should be construed in accordance with the invention is as follows: - "Nucleic acid sequence" - a sequence composed of DNA nucleotides, RNA nucleotides or a combination of both types and may includes natural nucleotides, chemically modified (see below) nucleotides and synthetic nucleotides. - "Amino acid sequence" - a sequence composed of any one of the 20 naturally appearing ammo acids, amino acids which have been chemically modified (see below), or composed of synthetic amino acids. - "Original sequence" - the nucleic acid sequence as depicted in SEQ ID NO: l, 2 and 5 more preferably in SEQ ID NO:39 or SEQ ID NO:40 or the amino acid sequence as depicted in SEQ ID NOs:3. 4 and preferably 41 and 42. from which the homologues and fragmented sequences of the invention are derived. - "homologues nucleic acid sequence" - A nucleic acid sequence having at least 90% identity (see below) to the nucleic acid sequences shown in SEQ ID NO: 1, ι o SEQ ID NO :2. and more preferably with the nucleic acid sequences shown in SEQ ID NO:39 or SEQ ID NO:40 and fragments (see below) of the said sequences. These sequences may include sequences coding for a novel, naturally occurring, alternatively spliced variant of the native genes or truncated, mutated or fragmented forms of the original sequences (i.e. the sequences shown in SEQ ID NO's 1, 39 and 15 40). - "homologues amino acid sequence"- also referred at times as the 'homologues protein " or "homologues product" ' - is an amino acid sequence encoded by the nucleic acid sequence shown in SEQ ID NO: 1. SEQ ID NO:2 and more preferably in SEQ ID NO:39 or SEQ ID NO:40 or by homologues or fragments of said nucleic acid 0 sequence. The amino acid sequence may be a peptide, a protein, as well as peptides or proteins having chemically modified amino acids (see below) such as a glycopeptide or glvcoprotein or wherein one or more amino acids has been added, deleted, or substituted (see below) as compared to the amino acid sequence shown in SEQ ID NO: 3 and SEQ ID NO:4 and more preferably as compared to the amino acid 5 sequence shown in SEQ ID NO:41 or SEQ ID NO:42, as well as, fragments (see below) or homologues thereof. - "Conservative substitution " - refers to the substitution of an amino acid in one class by an amino acid of the same class, where a class is defined by common physicochemical amino acid side chain properties and high substitution frequencies in -4- homologous proteins found in nature, as deteπnined. for example, by a standard Dayhoff frequency exchange matrix or BLOSUM matrix. [Six general classes of amino acid side chains have been categorized and include: Class I (Cys); Class II (Ser. Thr, Pro. Ala. Gly): Class III (Asn. Asp. Gin, Glu); Class IN (His, Arg, Lys); Class N (He, Leu. Val. Met): and Class NI (Phe. Tyr. Trp). For example, substitution of an Asp for another class III residue such as Asn. Gin, or Glu. is a conservative substitution. - "Non-conservative substitution " - refers to the substitution of an amino acid in one class with an amino acid from another class; for example, substitution of an Ala, a class II residue, w ith a class III residue such as Asp. Asn. Glu. or Gin. - "Chemically modified" - when referring to the product of the invention, means a product (protein or peptide) where at least one of its amino acid resides is modified either by natural processes, such as processing or other post-translational modifications, or by chemical modification techniques which are well known in the art. Among the numerous known modifications typical, but not exclusive examples include: acetylation. acvlation. amidation. ADP-ribosylation. glycosylation, GPI anchor formation, covalent attachment of a lipid or lipid derivative, methylation, myristlyation, pegylation. prenylation. phosphorylation, ubiqutination. or any similar process. - "Biologically functional sequence" - which may at times be referred to as the "desired sequence" or as " biologically functional homologues or fragments thereof refers to a nucleic acid sequence which, upon its expression provides the host cell (target cell, tissue etc.) with some sort of a biological activity similar to that ascribed to the original sequence, for example, with a measurable enzymatic activity. - "Optimal alignment" - is defined as an alignment giving the highest percent identity score. Such alignment can be perfoπned using a variety of commercially available ~> sequence analysis programs, such as the local alignment program LALIGΝ using a ktup of 1. default parameters and the default PAM. A preferred alignment is the one performed using the CLUSTAL-W program from MacNector (TM), operated with an open gap penaln of 10.0. an extended gap penalty of 0.1. and a BLOSUM similarity matrix. If a gap needs to be inserted into a first sequence to optimally align it with a second sequence, the percent identity is calculated using only the residues that are paired w ith a corresponding amino acid residue (i.e.. the calculation does not consider residues in the second sequences that are in the "gap" of the first sequence). - "Having at least 90% identity" - with respect to two amino acid or two nucleic acid sequences, refers to the percentage of residues that are identical in the two sequences when the sequences are optimally aligned. Thus, 90% amino acid sequence identity means that 90% of the amino acids in two or more optimally aligned polypeptide sequences are identical. - "Construct" - is a nucleic acid molecule that includes the desired coding nucleic acid sequence ( i.e.. which upon its expression provides the target cell with the desired functionality). The isolated nucleic acid molecule may include the nucleic acid sequence shown in SEQ ID NO's 1 and 2 and more preferably the nucleic acid sequence shown in SEQ ID NO:39 and 40. or homologues and fragments thereof, as an independent insert; or may include the said sequences fused to an additional coding sequences, encoding together a fusion protein in which the desired coding sequence is the dominant coding sequence (for example, the additional coding sequence may code for a signal peptide); the desired nucleic acid sequence may be in combination with non-coding sequences, e.g., introns or control elements, such as promoter and terminator elements or 5' and/or 3' untranslated regions, effective for expression of the desired coding sequence in a suitable host: or may be a vector in which the functional protein coding sequence is a heterologous. - "Expression vector" - refers to vectors that have the ability to incorporate and express heterologous DNA fragments in a foreign cell. Many prokaryotic and eukaryotic expression vectors are lαiown and/or commercially available. Selection of appropriate expression vectors is within the knowledge of those having skill in the art. - "Deletion " - is a change in either nucleotide or amino acid sequence in which one or more nucleotides or amino acid residues, respectively, are absent. -6- - "Insertion " or "addition" - is that change in a nucleotide or amino acid sequence which has resulted in the addition of one or more nucleotides or amino acid residues. respectively, as compared to the naturally occurring sequence. - "Substitution " - replacement of one or more nucleotides or amino acids by different nucleotides or amino acids, respectively. As regards amino acid sequences the substitution ma)' be conservative or non- conservative. - ' Detection - refers to a method of detection of a disease, disorder, pathological or normal condition. This term may refer to detection of a predisposition to a disease as well as for establishing a suitable prognosis by deteπnining the severity of the disease. - "Probe" - the variant nucleic acid sequence, or a sequence complementary therewith, when used to detect presence of other similar sequences in a sample. The detection is carried out by identification of hybridization complexes between the probe and the assayed sequence. The probe may be attached to a solid support or to a detectable label. An example of a nucleic acid sequence which may be used as a probe is a fragment derived from the 5' conserved region of the said nucleic acid sequences of the invention. SUMMARY OF THE INVENTION The present invention is based on the finding that at least two genes, P 1 and P c are responsible for the resistance of Cucumis melo PI 12411 IF (PI) plant to downy mildew . These two genes have now been characterized by their nucleic acid sequence and transformed into to two plant types of plant, tobacco and melon, which were shown to be resistant to the fungal diseases. Thus, by its first aspect, the present invention relates to novel nucleic acid sequences comprising or consisting of a sequence selected from the group of sequences set forth in SEQ ID NO: 1. SEQ ID N0.2. SEQ ID NO:39 and SEQ ID NO:40; biologically functional homologue sequences thereof, i.e. having at least 90% identity with these sequences: a nucleic acid sequence which, under stringent hybridization conditions, hybridized with one of said sequences: a nucleic acid sequence which codes for the same expression product as that coded by SEQ ID NO: l. SEQ ID NO:2, SEQ ID NO:39 or by SEQ ID NO:40 or for an expression product having the same biological activity as the product coded by these sequences or any biologically functional homologue or fragment thereof. The person versed in the art may know how to determined the conditions required in order to facilitate hybridization of a nucleic acid sequence with the nucleic acid sequences depicted in SEQ ID NO: 1, SEQ ID NO:2. SEQ ID NO:39 or SEQ ID NO:40. Il should be noted that SEQ ID NO:39 and SEQ ID NO:40 are in fact the complete sequences of. respectively. SEQ ID NO: l and SEQ ID NO:2. The completion of the sequences was achieved by further perfoπning the RACE reaction as described below . The nucleic acid sequence of the invention may be a coding or non-coding sequence, the non-coding sequence is typically complementary to that of SEQ ID NO: 1. SEQ ID NO:2. SEQ ID NO:39 or SEQ ID NO:40. or complementary to a sequence having at least 90%) identity to said sequences or a biologically functional fragment thereof. The complementary sequence may be a nucleic acid sequence which hybridizes with at least part of the sequence depicted in SEQ ID NO: l, SEQ ID NO:2, SEQ ID NO:39 or SEQ ID NO:40 as long as the activity of the encoded product is preserved, i.e. upon the nucleic acid sequence's expression in a host cell or tissue, resistance to at least one fungal disease is conferred to said host. The complementary sequence ma) 7 be a DNA sequence or a mRNA. The present invention further pertains to an amino acid sequence encoded by the nucleic acid sequence of the invention and to biologically functional fragments or homologues of said amino acid sequence in which one or more of the amino acid residues has been substituted (by conservative or non-conservative substitutions) added to. deleted or chemically modified. According to one embodiment, the amino acid sequence of the invention is that comprising or having the sequence substantially as set forth in SEQ ID NO:3. According to a further embodiment, the amino acid sequence is that comprising or having the sequence substantially as shown in SEQ ID NO:4 which is in fact a fragment of SEQ ID NO:3. Yet further, the amino acid sequence of the invention is that comprising or having the amino acid sequences as shown in SEQ ID NO:41 or in SEQ ID NO:42. It should be noted that the later two sequences are the complete AT I and AT2 sequences comprising the two former ones (i.e. SEQ ID NO:3 and SEQ ID NO:4). Due to the degenerative nature of the genetic code, a plurality of alternative nucleic acid sequence, beyond SEQ ID NOT. SEQ ID NO:2. SEQ ID NO:39 and SEQ ID NO:40 may code for the same amino acid sequence and thus, such sequences, which may be referred to as functional homologues or variants of the nucleic acid sequences depicted in SEQ ID NO's: l. 2. 39 and 40. also foπn part of the present invention, as long as they code for a protein or peptide product having a similar biological activity to that of the original product. The present invention further provides constructs, e.g. expression vectors or cloning vectors comprising one or more of the above nucleic acid sequences. The constructs may be used either for the production of a transgenic plant via its transformation or transfection with the nucleic acid of the invention or for mass production of the amino acid sequence encoded by the nucleic acid sequence of the invention, for example, via the transformation of the latter into a suitable host cell, for example, by the use of agro-bacterium derived vectors. According to another aspect of the invention, there is provided a host cell or tissue or a plant transformed with at least one of the nucleic acid sequences of the invention or with biological functional homologues and fragments thereof as defined above. The host cell or tissue may be. inter alia, a plant cell or a microbial cell or an)' other cell type or tissue as may be known to the person skilled in the art and which may incorporate into its cellular membrane and if desirable, into its genome, the nucleic acid sequence of the invention. The invention also provides methods for producing a transgenic plant having resistance to at least one fungal disease and preferably to downy mildew disease. According to one embodiment, the method comprises the steps of: (a) providing a plant cell: (b) introducing into said plant cell the nucleic acid sequence of the invention: (c) regenerating from said plant cell a plant. Finally, the invention also pertains to the use of the nucleic acid sequence of the invention for the production of a transgenic plant, the plant having resistance to fungal disease, particularly such caused by Pseudoperonospora cubensis or by Peronospora tabacina or any other uses of said sequences, as may be known to those versed in the art. BRIEF DESCRIPTION OF THE FIGURES In order to understand the invention and to see how it may be carried out in practice, a preferred embodiment will now be described by way of a non-limiting example only, with reference to the accompanying figures, in which: Figure 1 shows two DNA fragments (500 bp referred to herein as a fragment of AT2. and 1035 bp referred to herein as a fragment of ATI) produced by PCR from cDNA. the latter synthesized from RNA taken from PI 12411 IF. The 500 bp fragment was produced with upstream primers designated from peptide 6 (SEQ ID NO:9). and downstream primers designated from peptide 2 (SEQ ID NO:6). The 1035 bp fragment was produced with upstream primer from peptide 6 and dow nstream primers from peptide 1 (SEQ ID NO:5). Figure 2 shows the RACE 375' DNA products of the 2 DNA fragments show in Fig. 1. Lane 7:A 1026 bp DNA product of 3'-RACE of the 1035 bp fragment. Lane 2: A 1 100 bp DNA product of 3'-RACE of the 500 bp fragment. Lane 3: An 800 bp DNA product of 5'-RACE of the 1035 bp fragment. Lane 4: A 564 bp DNA product of 5'-RACE of the 500 bp fragment. Figure 3 shows the design of the RACE reaction used to obtain one of the genes ( 1428 bp. the coding sequence starting from the first ATG in SEQ ID NOT encoding for P45. The 1035 bp fragment was used to obtain the two ends of the gene (800 bp upstream and 1026 bp downstream). The two ends share a region of 398 bp. Figure 4 show s the deduced amino acid sequence (SEQ ID NO:3) of the 1428 bp DNA product (SEQ ID NOT) obtained from the RACE reaction shown in Fig. 3. In the amino acid sequence, the underlined letters represent peptides 6, 2, and 5 of the P45 protein of PI 12411 IF. The double underlined region (71 amino acids) is homologous (86%) to either Alanine-Glyoxylate-Aminotransferase (AGT) or Seπne-Glyoxylate Aminotransferase (SGA). (This region was also found in the products derived from the 500 bp region shown in Fig. 1). Figure 5 shows the amino acid sequence (SEQ ID NO:4) deduced from the AT2 nucleic acid fragment (SEQ ID NO:2). The underlined letters represent the peptide ι o ing the SEQ ID NO:6 derived from the P45 protein of PI 12411 IF. Figure 6 show s some of the degenerated oligonucleotides derived from the peptidic fragments of P45. From the peptide having the sequence shown in SEQ ID NO:5 degenerated oligonucleotides having the SEQ ID NOsT l to 18 were obtained; from the peptide having the sequence shown in SEQ ID NO:6 degenerated 15 oligonucleotides having the SEQ ID NOs: 19 to 26 were obtained; from the peptide haλ ing the sequence shown in SEQ ID NO: 10 degenerated SEQ ID NO ' s: 27 to 38, were obtained. The numbers of the sequences are indicated on the left margin of the figure. DETAILED DESCRIPTION OF THE INVENTION 0 EXAMPLE 1- General The nucleic acid sequence of the invention includes nucleic acid sequences which encode the P45 protein, or biologically functional homologues or fragments thereof. The nucleic acid sequence may alternatively be a sequence (preferably biologicall)' functional) complementary to the above coding sequence, or to a region of 5 said coding sequence capable, under suitable conditions to hybridize with the coding sequence. The nucleic acid sequence may be in the foπn of a DNA or an RNA and includes messenger RNA. synthetic RNA and DNA (cDNA and genomic DNA). The DNA may be double stranded or single-stranded and if single-stranded may be the coding strand or the non-coding strand (anti-sense, complementary) strand. The nucleic acid ma)' also both include dNTPs, rNTPs as well as non-naturally occurring sequences. The sequence may also be a part of a hybrid with another moiety, such as an amino acid sequence. 5 In a general embodiment, the nucleic acid sequence homologues have at least 90% homology with the sequence depicted in SEQ ID NO: l. SEQ ID NO:2. SEQ ID NO:39 or SEQ ID NO:40, preferably 95% and more preferably 99% homology therewith, or with a region thereof, e.g. at the N-teπninus thereof. The nucleic acid sequence may include the coding sequence by itself, a 10 combination of fragments of the coding sequence or a region of the coding sequence in combination with additional coding sequences, such as those coding for fusion proteins or signal peptides: in combination with non-coding sequences, such as introns and control elements, promoter and teπnination elements or 5' and/3' untranslated regions, effective for expression of the coding sequence in a suitable host, and/or in a vector or 15 host environment in which the nucleic acid sequence of the invention is introduced as a heterologous sequence. The nucleic acid sequence of the present invention may also have the biologicall) functional coding sequence fused in frame to a marker sequence which allows for example, the purification of the protein product. The marker sequence may 20 be. for example, hexahistidine tag to provide for purification of the mature protein fused to the marker in the case of a bacterial host. Also included in the scope of the invention are fragments of the nucleic acid sequence as defined above, at times, referred to herein as oligonucleotides. The fragments may be used as probes, primers and when complementary also as antisense ~>- agents and the like, according to lαiown methods. The nucleic acid sequences may be obtained by screening cDNA libraries using oligonucleotide probes which can hybridize to or PCR-amplify nucleic acid sequences encoding the biologicall) functional products disclosed herein. cDNA libraries prepared from a variety of tissues are commercially available and procedures for screening and isolating cDNA clones are well-known to those of skill in the art. Such techniques are described in. for example. Sambrook et al. (1989) Molecular Cloning: A Laboratory Manual (2nd Edition). Cold Spring Harbor Press. Plainview, N.Y and Ausubel FM et al. ( 1 89) Current Protocols in Molecular Biology. John Wiley & Sons, New York. N.Y The nucleic acid sequence may be extended to obtain upstream and downstream sequences such as promoters, regulatory elements, and 5' and 3' untranslated regions (UTRs). Extension of the available transcript sequence may be perfonned by numerous methods known to those of skill in the art. such as PCR or primer extension (Sambrook et al, supra), or by the RACE method using, for example, the Marathon RACE kit (Clontech. Cat. P- Kl 802- 1 ). as exemplified herein below. Alternatively, the technique of "restriction-site" PCR (Gobinda et al. PCR Methods Applic. 2:318-22. (1993)), which uses universal primers to retrieve flanking sequence adjacent a lαiown locus, may be employed. First, genomic DNA is amplified in the presence of primer to a linker sequence and a primer specific to the known region. The amplified sequences are subjected to a second round of PCR with the same linker primer and another specific primer internal to the first one. Products of each round of PCR are transcribed with an appropriate RNA polymerase and sequenced using reverse transcriptase. Inverse PCR can be used to amplify or extend sequences using divergent primers based on a lαiown region (Triglia. T. et al, Nucleic Acids Res. 16:8186, ( 1988)). The primers may be designed using OLIGO(R) 4.06 Primer Analysis Software ( 1992: National Biosciences Inc, Plymouth, Minn.), or another appropriate program, to be 22-30 nucleotides in length, to have a GC content of 50% or more, and to anneal to the target sequence at temperatures about 68-72°C. The method uses several restriction enzymes to generate a suitable fragment in the lαiown region of a gene. The fragment is then circularized by intramolecular ligation and used as a PCR template. Capture PCR (Lagerstrom. M. et al, PCR Methods Applic. 1 : 111-19, (1991)) is a method for PCR amplification of DNA fragments adjacent to a lαiown sequence in human and yeast artificial chromosome DNA. Capture PCR also requires multiple restriction enzyme digestions and ligations to place an engineered double-stranded sequence into a flanking part of the DNA molecule before PCR. Another method which may be used to retrieve flanking sequences is that of Parker. J.D.. et al, Nucleic Acids Res., 19:3055-60, (1991)). Additionally, one can use PCR. nested primers and PromoterFinder™ libraries to "walk in" genomic DNA (Promoterf inder™: Clontech. Palo Alto, CA). This process avoids the need to screen libraries and is useful in finding intron/exon junctions. Preferred libraries for screening for full length cDNAs are ones that have been size-selected to include larger cDNAs. Also, random primed libraries are preferred in that they will contain more sequences which contain the 5' and upstream regions of genes. Λ randomly primed library may be particularly useful if an oligo d(T) library does not yield a full-length cDNA. Genomic libraries are useful for extension into the 5' non-translated regulatory region. The nucleic acid sequences and oligonucleotides of the invention can also be prepared by solid-phase methods, according to lαiown synthetic methods. Typically, fragments of up to about 100 bases are individually synthesized, then joined to form continuous sequences up to several hundred bases. The nucleic acid sequence of the invention is preferably used for conferring plants, such as. Citrullus lanatus. Cucurbita moschata, Cucurbita pepo, Luffa sp., Lagenaria sp. Momordica sp.. and particularly Cucumis melo, with resistance against at least one fungal disease. According to one embodiment, the nucleic acid sequence of the invention, upon its expression, provides the plant transfonned therewith, with resistance to a disease caused by Pseudoperonospora cubensis being preferably the downy mildew disease. The expression of the nucleic acid of the invention results in the foπnation of a biologicall)' functional protein or. at times, a biological functional fragment thereof. The encoded protein was found to have high homology to the aminotransferase proteins family (not shown) and thus, it is suggested that the coding product of the nucleic acid sequence of the invention is an aminotransferase protein (enzyme) or a biological functional fragment thereof. According to one embodiment, the coded protein comprises or has the amino acid sequence substantially as set forth in SEQ ID NO:3 or in SEQ ID NO:4 and to functional homologues and fragments thereof. More preferably, the coded protein comprises or has the amino acid substantially as set forth in SEQ ID NO:41 or in SEQ ID NO:42. It should be noted that foπner sequence (i.e. SEQ ID NO:41) is the product encoded by SEQ ID NO:39 while the later is encoded by SEQ ID NO:40. These two protein sequences contain 401 amino acid residues and share 93% homolog) . Further, both sequence contain the six peptides isolated from P45 (SEQ ID Nos: 5- 10). Each of these protein products, biologically functional homologues and fragments thereof, when present or expressed in a plant or plant cell confers the same with resistance to at lease one fungal disease, being preferably downy mildew . As described above, the invention also pertains to a construct comprising at least one nucleic acid sequence of the invention. The constructs may include, for example, a plasmid. a phage or vector, e.g. a viral vector, into which a nucleic acid sequence of the invention has been inserted, in a forward or reverse orientation. In a preferred aspect of this embodiment, the construct further comprises regulatory elements which drive transcription of the sequence in a host cell, including, for example, a promoter, operably linked to the sequence. Once the construct is within the cell membrane, integration into the endogenous chromosomal material either will or will not occur. Large numbers of suitable vectors and promoters are lαiown to those skilled in the art, such as the pGEM Eas) Vector (Promega) exemplified hereinbelow, and are commercially available. The nucleic acid sequence is inserted into the host cell, either as a naked DNA or as part of a construct. Alternatively, the nucleic acid sequence may be inserted in the form of an RNA. for example by the technique known as RNA interference (RNAi) [see. for example. Watehouse P.W. et al. PNAS USA 95: 13959-13964 (1998)]. The present invention also relates to host cells which are genetically engineered with the nucleic acid of the invention. The engineered host cells may be cultured in conventional nutrient media modified as appropriate for activating promoters, selecting transformants or amplifying the expression of the resistance conferring nucleic acid sequence. The culture conditions, such as temperature, pH and the like, are those pre\ iousl) used w ith the plant from which the cells are derived or with any other suitable host cell and will be apparent to those skilled in the art. The nucleic acid sequences of the present invention may be included in any one of a variety of expression vectors for expressing a product. Such vectors include chromosomal, nonchromosomal and synthetic DNA sequences, e.g., derivatives of 35S CaMV or of endogenous sequences. However, any other vector may be used as long as it is replicable and viable in the host. The appropriate nucleic acid sequence may be inserted into the vector by a variety of procedures. In general, the sequence is inserted into an appropriate restriction endonuclease site(s) by procedures lαiown in the art. Such procedures and related sub-cloning procedures are deemed to be within the scope of those skilled in the art. The expression vector may also contain a ribosome binding site for translation initiation, and a transcription teπninator. The vector may also include appropriate sequences for modulating (amplifying or reducing) expression. In addition, the expression vectors preferably may contain one or more selectable marker genes to provide a phenotypic trait for selection of transfoπned host cells such as dihydrofolate reductase or neomycin resistance for eukaryotic cell culture, or such as tetracycline or ampicillin resistance in E.coli. The vector containing the appropriate nucleic acid sequence as described above, as well as an appropriate promoter or control sequence, may be employed to transfoπn an appropriate host to permit the host to express the protein. Examples of appropriate expression hosts include: bacterial cells, such as E.coli or agro-bacterium and most preferably plant cells. The selection of an appropriate host is deemed to be within the scope of those skilled in the art from the teachings herein. ln bacterial systems, a number of expression vectors may be selected depending on the use intended for the resistance product. For example, when large quantities of the resistance product are needed vectors which direct high level expression of fusion proteins that are readily purified may be desirable. Such vectors include, but are not 5 limited to. multifunctional E.coli cloning and expression vectors such as Bluescript(K) (Stratagene). in which the protein coding sequence may be ligated into the vector in-frame with sequences for the amino-tenninal Met and the subsequent 7 residues of beta-galactosidase so that a hybrid protein is produced; pIN vectors (Van Heeke & Schuster ./ Biol. Chem. 264:5503-5509. ( 1989)); pET vectors (Novagen. Madison WI); i o pGEM Easy vectors (Programa) and the like. In cases where plant expression vectors are used, the expression of a sequence encoding the biologically functional product may be driven by any of a number of promoters. For example, viral promoters such as the 35S and 19S promoters of CaMV (Brisson el al. Nature 310:511-514. (1984)) may be used alone or in combination with 15 the omega leader sequence from TMV (Takamatsu et al.. EMBO J., 6:307-311 , ( 1987)). Alternatively, plant promoters such as the small subunit of RUBISCO (Coruzzi et al, EMBO J. 3: 1671 - 1680. ( 1984); Broglie et al. Science 224:838-843, (1984)); or heat shock promoters (Winter J and Sinibaldi R.M.. Results Probl. Cell Differ, 17:85-105. ( 1991 )) may be used. These constructs can be introduced into plant cells by direct DNA 0 transformation or pathogen-mediated transfection. For reviews of such techniques, see Flobbs S. or Murry L.E. ( 1992) in McGraw Hill Yearbook of Science and Technology. McGraw Hill. New York. N.Y, pp 191-196; or Weissbach and Weissbach (1988) Methods for Plant Molecular Biology, Academic Press. New York. N.Y, pp 421-463. Specific initiation signals may also be required for efficient translation of the 5 protein coding sequence. These signals include the ATG initiation codon and adjacent sequences. In cases where the resistance product coding sequence, its initiation codon and upstream sequences are inserted into the appropriate expression vector, no additional translational control signals may be needed. However, in cases where only coding sequence, or a portion thereof, is inserted, exogenous transcriptional control signals including the ATG initiation codon must be provided. Furtheπnore, the initiation codon must be in the correct reading frame to ensure transcription of the entire insert. Exogenous transcriptional elements and initiation codons can be of various origins, both natural and synthetic. The efficiency of expression may be enhanced by the inclusion of enhancers appropriate to the cell system in use [Scharf, D. et al, ( 1994) Results Probl. Cell Differ, 20: 125-62. (1994); Bittner et al, Methods in Enzymol 153:516-544. ( 1987)]. In a further embodiment, the present invention relates to host cells containing the above-described nucleic acid sequences and constructs. The host cell can be a eukaryotic cell, such as a plant cell, or a prokaryotic cell, such as a bacterial cell. Introduction of the nucleic acid sequence or construct into the host cell can be effected by agro-bacterium transformation or biolystic bombardment techniques as may be know n to those versed in the art. Cell-free translation systems can also be employed to produce proteins using RNAs derived from the constructs of the present invention. For long-term, high-yield production of the amino acid sequences, stable expression is preferred. For example, cell lines which stably express the biologically functional product may be transfoπned using expression vectors which contain viral origins of replication or endogenous expression elements and a selectable marker gene. Following the introduction of the vector, cells may be allowed to grow for 1-2 days in an enriched media before they are switched to selective media. The purpose of the selectable marker is to confer resistance to selection, and its presence allows growth and recover)' of cells which successfully express the introduced sequences from which a v hole plant may be derived. An) number of selection systems may be used to recover transfoπned cell lines as may be known to those versed in the art. These include antimetabolite. antibiotic or herbicide resistance or reporter genes, for example, dhfr which confers resistance to methotrexate [Wigler M.. et al, Proc. Natl. Acad. Sci. 77:3567-70, (1980)]; npt, which confers resistance to the aminoglycosides neomycin and G-418 [Colbere-Garapin, F. et al, J. Mυl Biol. 150: 1-14, (1981)] and als or pat, which confer resistance to chlorsulfuron and phosphinotricin acetyltransferase. respectively (Murry, supra). Additional selectable genes have been described, for example. trpB, which allows cells to utilize indole in place of tryptophan, or hisD. which allows cells to utilize histinol in place of histidine [Hartman S.C. and R.C. Mulligan. Proc. Natl Acad. Sci. 85:8047-51, ( 1988) ]. The use of visible markers has gained popularity with such markers as anthocyanins. beta-glucuronidase and its substrate. GUS, and luciferase and its substrates, lucifcrin and ATP. being widely used not only to identify transfoπnants, but also to quantify the amount of transient or stable protein expression attributable to a specific vector system [Rhodes. CA. et. al. Methods Mol. Biol, 55:121-131, (1995)]. Host cells transformed with one or more of the nucleic acid sequences encoding the resistance conferring product of the present invention may be cultured under conditions suitable for the expression and recovery of the encoded protein from cell culture. The protein product of the invention may also be expressed as a recombinant protein with one or more additional polypeptide domains added to facilitate protein purification. Such purification facilitating domains include, but are not limited to, metal chelating peptides such as histidine-tryptophan modules that allow purification on immobilized metals, protein A domains that allow purification on immobilized immunoglobulin. and the domain utilized in the FLAGS extension/affinity purification system (Immunex Corp. Seattle. Wash.). The inclusion of a protease-cleavable poh peptide linker sequence between the purification domain and protein product is useful to facilitate purification. One such expression vector provides for expression of a fusion protein compromising a resistance protein fused to a polyhistidine region separated by an enterokinase cleavage site. The histidine residues facilitate purification on IMIAC (immobilized metal ion affinity chromatography, [as described in Porath, et al. Protein Expression and Purification, 3:263-281, (1992)] while the enterokinase clea age site provides a means for isolating CLH polypeptide from the fusion protein. pGEX vectors (Promega. Madison. Wis.) may also be used to express foreign poh peptides as fusion proteins with glutathione S-transferase (GST). In general, such fusion proteins are soluble and can easily be purified from lysed cells by adsorption to ligand-agarose beads (e.g.. glutathione-agarose in the case of GST- fusions) followed by elution in the presence of free ligand. Follow ing transformation of a suitable host strain and growth of the host strain to an appropriate cell density, the selected promoter is induced by appropriate means (e.g.. temperature shift or chemical induction) and cells are cultured for an additional period. Cells are typically harvested by centrifugation. disrupted by physical or chemical means, and the resulting crude extract retained for further purification. Microbial cells employed in expression of proteins can be disrupted by any convenient method, including freeze-thaw cycling, sonication. mechanical disruption, or use of cell 1) sing agents, or other methods, which are well know to those skilled in the art. If required, the protein products can be recovered and purified from recombinant cell cultures by any of a number of methods well lαiown in the art, including ammonium sulfate or ethanol precipitation, acid extraction, anion or cation exchange chromatography, phosphocellulose chromatography, hydrophobic interaction chromatography. affinity chromatography, hydroxylapatite chromatography, and lectin chromatography. Protein refolding steps can be used, as necessary, in completing configuration of the mature protein. Finally, high perfoπnance liquid chromatography (HPLC ) can be employed for final purification steps. According to one embodiment, the host cell of the invention is a bacterial host cell, and more preferably E.coli which are transfoπned with the nucleic acid sequence of the invention using the commercially available pGEM Easy Vector system as described below . Alternatively, the host cell may be a plant cell, which after transformation with the nucleic acid sequence, is regenerated into a whole plant. The plant cell, under suitable conditions, e.g. appropriate temperature and nutrition, regenerates into a plant having resistance to at least one fungal disease (such plants are at times, referred to herein as the transgenic plant). The person versed in the art may know how to regenerate from a cell or cell culture a whole plant [see. for example. Dirks. R. et al. , Plant Cell Repr. 7:626-627 ( 1989)]. The plant cell may be of any suitable source, and preferably from the group of plants consisting of Citrullus lanatus, Cucurbita moschata. Cucurbita pepo. Luffa sp.. Lagenaria sp.. Momordica sp. or Solanicae. According to one preferred embodiment, the plant cell is derived from Cucumis melo plants and the fungal disease is preferably downy mildew. It ma)' be appreciated by those versed in the art that also descendants and clones of the transgenic plant will typically be resistant the specific disease and thus, any plant which is a sexually or an asexually propagated descendant or clone of the transgenic plant of the invention, also foπns part of the invention. The present invention also provides a method of producing a transgenic plant having resistance to at least one fungal disease, the method comprising the steps of- (a) providing a plant cell: (b) introducing into said plant cell the nucleic acid sequence or construct according to the invention; (c) regenerating from said plant cell a plant and optionally (d) sexually or asexually propagating or growing a descendent of the plant obtained in step (c). Preferably, the transgenic plants produced are resistant to Downey mildew disease. Evidently, any other use of the novel nucleic acid sequences of the invention form part of the present invention. For example, in addition to the above applications, the nucleic acid sequence of the invention may be used as a probe in detection methods as may be known to the artisans. EXAMPLE 2-Identification and characterization of nucleic acid sequences Materials and Methods Plant material Cucumis melo PI 12411 IF (F10) plants were grown in a greenhouse, in pots (0.51) containing a mixture of sandy loam, peat and veπniculite (2: 1 : 1 v/v/v). When the plants had 4-5 fully expanded leaves, they were taken for RNA extraction. RNA extraction For RNA extraction, leaf no. 2 was used. The plant tissue was ground to a fine pow der and homogenized under liquid nitrogen using a mortar and pestle. RNA was extracted using TRIREAGENT® of MRC [Chomezynski P, Biotechniques 15:532-537 ( 1993)] and its quality was evaluated spectrophotometrically using and by gel electrophoresis on 1% agarose. cDXA Complementary DNA (cDNA) was synthesized from the extracted RNA using the First-Strand cDNA. Synthesis Kit (Amersham Pharmacia Biotech). The primers pd(N)c random hexadenucleotides were used in the reaction. PCR The synthesized cDNA was amplified using the following constituents: 4μl cDNA. 5μl 10 X PCR buffer, lμl 20 mM dNTP mix, downstream and upstream primers - 2.5 LI Taq DNA polymerase for PCR (Takara) and H 2 0 to complete to 50 μl total reaction volume. Primer synthesis P45 was subjected to proteolysis and sequencing. For the determination of the nucleic acid sequences shown in SEQ ID NO ' sT, 2. six sequences were repeatedly characterized and include the following residues :- 1 . DVGVPVK (SEQ ID NO:5); 2. AICIVHNETATGVTNDLSK (SEQ ID NO:6); 3. RNNLSLGLGL (SEQ ID NO:7); 4. AYNLAYQAGLNK (SEQ ID NO:8); 5. LGSVAAASAYLON (SEQ ID NO:9); 6. NHLFVPGPVNIPEPVLRAMNRNNEDYR (SEQ ID NO: 10). SEQ ID NO: 39 and 40 were obtained after further applying the RACE reaction on the sequences obtained. These sequences, i.e. SEQ ID NO:39 and 40 are respectiveh' the complete gene sequences, referred to herein also as the complete ATI and AT2 sequences. I he nucleic acid sequences were used for constructing degenerate oligonucleotides in upstream and downstream directions, for PCR reactions. Several degenerated oligonucleotides primers were synthesized some of which are shown in Fig. 6. using nucleotides of Keystone-Biosource. on a scale of 0.2 μM with no purification. RACE reaction f or the RACE reaction. RACE Kit 573' of Boehringer Mannheim was used (Frohmann. 1994). DNA purification DNA bands were removed from the gels and purified with the aid of DNA Isolation Kit of Biological Industries (Israel). Cloning DNA fragments were cloned into pGEM Easy Vector Systems (Promega) and transformed to competent F. coli (Hd5α). Results and discussion Primers were synthesized by using the amino acid sequences of the 6 peptides obtained from the P45 protein. The primers, in pairs, were incorporated into PCR reactions in all possible upstream and downstream combinations. PCR was conducted with touchdown of 55-45°C for 10 cycles, and 20 cycles of 45°C. Two combinations produced a DNA band (Fig. 1). Lane 1 shows a 500 bp DNA band obtained from one combination of primers (referred to herein as a fragment of the AT2) and lane 2 shows a 1035 bp band obtained from another combination of primers (referred to herein as a fragment of the ATI). Both bands were purified, cloned in pGEM Easy Vector (Promega) and transformed into competent E.coli. The fragments were sequenced with T7 and SP6 primer. To obtain the two ends of each gene, RACE reactions were perfoπned (according to Boehringer Kit protocol as shown in Fig. 3). For this reaction, 6 primers were constructed, two for the 5' and one for the 3' ends. Fig. 2 shows the 4 bands of DNA products obtained: 564. 800. 1026 and 1100 bp. The DNA fragments were purified, cloned into pGEM Easy Vector, and sequenced. 1 he 5' and 3' end fragments of the 1035 gene matched the middle fragment and gaλ e homology which yielded 1428 bp (Fig. 3 and SEQ ID NOT). The amino acid sequence deduced therefrom is shown in Fig. 4 and in SEQ ID NO:3. The second gene referred to herein as the partial AT2 gene (SEQ ID NO:2) matched the 5' end RACE product, but not the 3' end product. This partial matching yielded about 1 kb fragment, starting from the N-terminus of the gene. The deduced amino acid sequence of the AT2 sequence is shown in Fig. 5. The final and complete sequences of the genes ATI and AT2 are shown in SEQ ID NO:39 and SEQ ID NO:40 while the amino acid sequences deduced therefrom are depicted, respectively, in SEQ ID NO ' s:41 and 42. The full length of the genes AT-1 and AT-2 sequences were also cloned into pGEM easy vector (Promega). The sequencing reaction were done with T7 and Sp7 primers that exist on the vector. Additional primers were synthesized to overlap and read the full length on both strands of the two genes. The primers were: For AT- 1 GCGACTGGGG TCAGGGTGCC AATCTTG (SEQ IDNO:43) CTAGGAACAT ACTGGCCATA CAC (SEQ ID NO:44) For AT-2 GGTCCATAAC GAGACAATCA CTAGTG (SEQ ID NO:45) GGAGGAACAA CAACAGCAGT CA (SEQ ID NO:46) AGTCGACGTG ATTGAAAGTG AATGG (SEQ ID NO:47) TTCGTATGGA TGATTGGGGA G (SEQ ID NO:48) The cloned genes have been found to have homology of 71 amino acids in the N -terminus regions starting from the putative start of the translation. The 1108 gene contains the binding site (GSQKAL) of the cofactor pyridoxal- 5 -phosphate (P-5-P) and the peroxisome target peptide (SRI) which is located in the 3' end of the protein. A search in the data bases (Gebebank, EMBL, DDBJ and PDP) with Blast program was conducted. This search revealed high homology >80% of the N-tenninus of the cloned genes to two genes from plants: Serine-Glyoxylate Aminotransferase (SGT) from Fritillaria agrestis (Pacino. unpublished Accesson No. AF 063900) and Alanine-Glyoxylate- Aminotransferase (AGT) from Arabidopsis thaliana (Liepman and Olsen. 1998. Accession No. AF063901). These two genes, SGT and AGT, are transaminases which exist specifically in peroxysomes, and bind to the cofactor P-5-P these findings, i.e. the high homology to transaminases in the N-teπninus of the genes, the existence of the binding site to the cofactor P-5-P, and the target peptide to the peroxysome. suggest that the P45 clones genes belong to a transaminase gene family. EXAMPLE 3- Plant transformation The complete AT-1 and AT-2 genes (SEQ ID NO's: 39 and 40) were cloned using Bglll and EcoRI restriction sites in 5' and 3 * respectively into pMON530-E9 binary vector [Roger S.G.. et al Methods in Enzymology. 153:253-2771987 (1987)]. The binary vector containing AT-1 and AT-2 were introduced into Agrobacterium tumefaciens strain EHA105 and used to perform melon transformation by co-cultivation the Agrobacterium with melon cotyledons according to the methodology described by Fang and Grumet [Fang. G. and Grumet. R. Plant Cell Rep. 9:160-164 (1990)]. Selection was done by the use of kanamycin and transgenic plants regenerated from these transformations were analyzed by PCR to verify that they contain the nucleic acid insertions. Resistance analysis of Tl transgenic plants L Tobacco Tl tobacco plants (cv Xanttii nc) and wild type plants (of the same culture) were grow n in 2L pots in a greenhouse. When reached the 12-14 leaf stage, a leaf from the top of the plant was dissected (leaf 'No. 3 " ). and placed on a moist filter paper in 20x20x3 cm plates. The leaf was spray inoculated with a sporangial suspension (suspension in H 2 0) of the fungal pathogen Peronospora tabacina which lead to the development of a blue mold which is indicative of the development of the downy mildew disease. The plates were incubated at 15°C (12 hours of light per day) to allow the infection and fungal spore to develop in the leave. Ten days post inoculation, disease development was assessed visually (infected tissue turned chlorotic and then necrotic) and fungal development was assessed by counting the number of spores produced in five leaf discs (3 cm 0). The spores were removed from the infected leaves with the aid of cytometer. 2. Melon Tl melon plants (cv BUI) and wild type (PI 12411 IF) plants were grown in a greenhouse in the same manner as describe in connection with the tobacco plants. When reached the 7-10 leaf stage, a leaf from the top of the plant (leaf 'No. 3") was removed, placed in a petri dish on a moist filter paper and spray-inoculated with sporangial suspension (also in H 2 0) of the fungal pathogen Pseudoperonospora cubensis. Dishes were incubated at 20°C (12 hours of light per day) for 10 days at which disease symptoms. Fungal spora production in the leave were assessed in a similar manner as described in connection with the tobacco transfoπned plant. Results In both cases. 10 days post inoculation, the control leaves were susceptible to the respective disease while the leave from the Tl plants of either the tobacco or melon transformed plants were found to be resistant to the disease. These results suggest that the nucleic acids of the present invention are efficient in providing plants transfonned therewith resistance to fungal diseases.

Claims: CLAIMS: 1. A nucleic acid sequence comprising the sequence selected from the group consisting of (a) the nucleic acid sequence substantially set forth in SEQ ID NO: 1, SEQ ID NO:2. SEQ ID NO:39 or SEQ ID NO:40; (b) a nucleic acid sequence having at least 90% identity with the sequence set forth in SEQ ID NOT , SEQ ID NO:2, SEQ ID NO:39 or SEQ ID NO:40 or with a region thereof; (c) a nucleic acid sequence which, under stringent hybridization conditions, hybridizes with the sequence set forth in SEQ ID NO: 1 , SEQ ID NO:2. SEQ ID NO:39 or SEQ ID NO.40; (d) a nucleic acid sequence which codes for the same expression product as that coded by SEQ ID NOT , SEQ ID NO:2, SEQ ID NO:39 or SEQ ID NO:40or for an expression product having the same biological activity as the product coded by SEQ ID NOT. SEQ ID NO:2, SEQ ID NO:39 or SEQ ID NO:40 and (e) biologically functional fragments of the sequence of (a) to (d). 2. The nucleic acid sequence of Claim 1. being a DNA or an RNA. 3. The nucleic acid sequence of Claim 2. wherein said DNA is a synthetic DNA, cDNA or genomic DNA and said RNA is a synthetic RNA or a messenger RNA. 4. The nucleic acid sequence of Claim 3, having the sequence as set forth in SEQ ID NO:39 or SEQ ID NO:40. 5. The nucleic acid sequence of any one of Claims 1 to 4. coding for a biologically functional protein or peptide. 6. The nucleic acid sequence of Claim 5 which, upon its expression, confers plants with resistance to at least one fungal disease. 7. The nucleic acid sequence of Claim 6, wherein said fungal disease is caused by Pseudoperonospora cubensis or by Peronospora tabacina. 8. The nucleic acid of Claim 7, wherein said fungal disease is downy mildew. 9. The nucleic acid sequence of any one of Claims 6 to 8. wherein said plant is selected from the group consisting of Citrullus lanatus. Cucurbita moschata, Cucurbita pepo. Luffa sp.. Lagenaria sp., Momordica sp.. and Cucumis melo. 10. The nucleic acid of Claim 9. wherein said plant is Cucumis melo. 11. The nucleic acid of any of Claims 6 to 8, wherein said plant is tobacco. 12. The nucleic acid sequence of Claim 5. wherein said protein is an aminotransferase. 13. An amino acid sequence encoded by the nucleic acid sequence of Claim 1 and biologically functional homologues or fragments of said amino acid sequence. 14. The amino acid sequence of Claim 13 comprising or having the sequence substantially as set forth in SEQ ID NO:3, SEQ ID NO:4, SEQ ID NO:41 or in SEQ ID NO:42. 15. The amino acid sequence of Claim 14, having the sequence as set forth in SEQ ID NO:41 or in SEQ ID NO:42. 16. The amino acid sequence of Claims 14 or 15 which confers a plant with resistance against at least one fungal disease. 17. The amino acid sequence of Claim 16. wherein said fungal disease is caused by Pseudoperonospora cubensis or by Peronospora tabacina. 18. The amino acid sequence of Claim 16, wherein said fungal disease is downy mildew. 19. The amino acid sequence of any one of Claims 15 to 17, wherein said plant is selected from the group consisting of Citrullus lanatus, Cucurbita moschata, Cucurbita pepo. Luffa sp.. Lagenaria sp., Momordica sp.. and Cucumis melo. 20. The amino acid sequence of Claim 18. wherein said plant is Cucumis melo. 21. The amino acid sequence of Claim 17. wherein said plant is tobacco. 22. The amino acid sequence of any one of Claims 13 to 21 which is an aminotransferase protein or a biologically functional fragment thereof. 23. A construct comprising the nucleic acid sequence of Claim 1 optionally operatively linked to at least one control element. 24. The construct of Claim 23 which, upon introduction into a host cell, results in the expression of said nucleic acid sequence in said cell. 25. A host cell transformed with the nucleic acid sequence of Claim 1. 26. The host cell of Claim 25, which is a microbial. 27. The host cell of Claim 25 being a plant cell. 28. The host cell of Claim 27, wherein said plant is selected from the group consisting Citrullus lanatus, Cucurbita moschata, Cucurbita pepo, Luffa sp., Lagenaria sp.. Momordica sp., and Cucumis melo. 29. The host cell of Claim 28 which is Cucumis melo. 30. The host cell of Claim 25, which is tobacco. 31. A plant comprising the cell of any one of Claims 25 to 30. 32. A plant transformed with one or more of the nucleic acid sequences of Claim 1. 33. A plant cell transformed with one or more of the nucleic acid sequences of Claim 4. 34. The plant of any one of Claims 31 to 33, having resistance to at least one fungal disease. 35. The plant of Claim 34, wherein said fungal disease is caused by Pseudoperonospora cubensis or by Peronospora tabacina. 36. The plant of Claim 34. wherein said disease is downy mildew disease. 37. A plant which is a sexually or an asexually propagated descendant or clone of the plant of any one of Claims 31 to 36. 38. A transgenic plant substantially as described in the specification. 39. A method of producing a transgenic plant having resistance to a fungal disease caused by a phatogenic fungal said method comprises the steps of:- (a) providing a plant cell; (b) introducing into said plant cell the nucleic acid sequence according to Claim 1 : (c) regenerating from said plant cell a plant. 40. 1 he method of Claim 39. further comprising the step of sexually or asexually propagating or growing a descendent of the plant obtained in step (c). 41. The method of Claim 39 or Claim 40. wherein said nucleic acid sequence is introduced into said plant cell as a naked DNA or as part of a construct. 42. The method of any one of Claims 39 to 41 , wherein said nucleic acid sequence is expressed in said plant, thereby conferring the same with resistance to said fungal. 43. The method of Claim 36. wherein said fungal is Pseudoperonospora cubensis or by Peronospora tabacina. 44. Use of a nucleic acid sequence of Claim 1 in the production of a plant having resistance to a fungal disease caused by Pseudoperonospora cubensis.

Inventors: COHEN YIGAL, KENIGBUCH DAVID, COHEN, YIGAL, KENIGBUCH, DAVID
Applicants: COHEN YIGAL, KENIGBUCH DAVID, UNIV BAR ILAN, BAR ILAN UNIVERSITY, COHEN, YIGAL, KENIGBUCH, DAVID
Application year: 2001
Main classification: C12N15
IPC codes: C07K14, C12N9, C12N15